Hosted by the Korea Science AI Forum

Key researchers and corporate representatives in the domestic bio artificial intelligence (AI) and AI-driven drug development sectors gathered in one place to discuss the gap between technological advancements and real-world industrial applications, as well as strategies to overcome these challenges.


The 'Bio AI Symposium,' hosted by the Korea Science AI Forum and co-organized by the Seoul National University Bio-AI Research Group, KAIST Intelligent Chemistry Lab, Gallux, and Intervest, was held on March 31 at the Global Education Center for Engineers at Seoul National University in Gwanak-gu, Seoul.


Participants of the 'Bio AI Symposium' held on the 31st at Seoul National University in Gwanak-gu, Seoul, are taking a group photo. Galaxy  <br>Photo by Galaxy

Participants of the 'Bio AI Symposium' held on the 31st at Seoul National University in Gwanak-gu, Seoul, are taking a group photo. Galaxy
Photo by Galaxy

View original image

This event, under the theme "The Bio AI-Reality Gap: Where Does It Exist and How Can We Bridge It?", was organized to discuss not only AI-based drug discovery but also the broader changes and strategies within the bio industry.


The morning session, titled "How Far Has AI-Driven Drug Development Come?", focused on the current state and future direction of AI-based drug development.


The panel included Chaok Seok, CEO of Gallux and professor at Seoul National University; Kim Wooyeon, CEO of HITS and professor at KAIST; Namjin Jung, Global New Drug Development Advisor; Taeyoung Yoon, CEO of Oscotec; and Junhee Pyo, Director of the AI New Drug Research Institute at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. The discussion emphasized that Korean AI technology is achieving meaningful results in both biologic drugs and small molecule drug sectors, highlighting the need for strategic approaches to expand into global markets.


The afternoon session, under the theme "Where Is Bio AI Heading?", explored the future direction of AI-integrated research across the life sciences.


Professor Kim Vinnari from the Department of Biological Sciences at Seoul National University delivered a keynote address, delving deeply into the major challenges and practical issues that AI must address in RNA biology and therapeutics.


The subsequent panel discussion featured Professor Hyunsook Lee (Seoul National University), Professor Youngil Ko (Seoul National University), Professor Junhwan Bae (KAIST), Professor Myunghwan Choi (Seoul National University), and Professor Jinwoo Nam (Hanyang University). They discussed the changes AI is bringing to research methodologies and the future direction of research, focusing on brain science, aging, and rejuvenation studies.


Chaok Seok, CEO of Gallux, who co-organized the event, stated, "With the recent accumulation of bio knowledge and data, the integration of AI is ushering bio academia and industry into a new inflection point. Especially in the early stages of drug development, these changes are already becoming a reality, and AI is influencing research methodologies and the overall industrial structure. This event was an opportunity to discuss future strategies for the bio sector as a whole—not just drug development—centered on the question of how to lead this transition."



This symposium was also linked to the K-Moonshot initiative announced by the government, sparking discussions on real-world challenges that must be addressed in the bio field. Industry insiders expect that such discussions will serve as an important starting point for securing the competitiveness of Korea’s bio AI research and industry, as well as for building a robust ecosystem.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing